ArticlePloS one2026
Association analysis of Mycoplasma pneumoniae 23S rRNA gene mutation with refractory Mycoplasma pneumoniae pneumonia in children.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Application of Clinical Indicators in the Early Prediction of RefractoryClinical pediatrics · 2026Article
- Immunopathogenesis, molecular phenotyping, and host-directed interventions for severe pediatricFrontiers in cellular and infection microbiology · 2026Review
- Doxycycline for Macrolide-ResistantInfection and drug resistance · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the current status of macrolide resistance in Mycoplasma pneumoniae (MP) and analyzes the relationship between mutations at the 23S rRNA A2063G and/or A2064G loci and refractory Mycoplasma pneumoniae pneumonia (RMPP).
methodsA retrospective analysis was conducted on 205 hospitalized children diagnosed with MPP at the Third Ward of the department of paediatrics, Jingzhou Central Hospital, from October 2023 to October 2024. Diagnosis was confirmed by pharyngeal MP nucleic acid testing and MP antibody titers (MP-Ab ≥ 1:160). All patients were screened for macrolide-resistant gene mutations (A2063G/A2064G). Patients were categorized based on the presence of macrolide-resistant gene mutations and RMPP diagnosis. Clinical features, laboratory results, and treatments were compared between groups. Multiple logistic regression was used to identify independent risk factors for RMPP.
resultsAmong 205 children with MPP, 157 (76.6%) harbored A2063G/A2064G mutations. Of the 77 children with RMPP, 71 (92.2%) carried these mutations, showing a significant association (P < 0.05). Compared to the non-resistant group, children with resistant mutations had prolonged fever duration, delayed defervescence after azithromycin, and required more bronchoscopic alveolar lavage (P < 0.05). The RMPP group exhibited more severe symptoms, longer fever and hospital stays, higher inflammatory markers (CRP, LDH, D-dimer, ESR, PCT; P < 0.001), and more frequent pulmonary consolidation, pleural effusion, plastic bronchitis, and extrapulmonary involvement. Multivariate analysis identified macrolide-resistant mutations, fever duration, and D-dimer level as independent risk factors for RMPP.
conclusionThe widespread macrolide resistance in M. pneumoniae (76.6% in this cohort) was associated with point mutations at the A2063G and/or A2064G loci in the 23S rRNA gene. The development of RMPP is linked to macrolide-resistant mutations, duration of fever and D-dimer levels. D-dimer emerged as the most predictive risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.